Reporting from the ESMO Congress 2021, Helen Gogas discusses the results of a phase II study of ipilimumab and nivolumab plus tocilizumab aiming to reverse steroid refractory toxicity from ICI in patients with metastatic melanoma. She also covers the MASTERKEY-265 phase III study testing the efficacy of pembrolizumab plus talimogene laherparepvec or placebo in advanced melanoma and the 3-year outcomes from the CheckMate 204 study of the nivolumab + ipilimumab combination in patients with brain metastases from melanoma.
1040O - Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma - Dr Jeffrey Weber, US
1037O - MASTERKEY-265: A phase 3, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL) - Prof Helen Gogas, GR
1039MO - CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM) - Dr Kim Margolin, US
This video is part of a sponsored track. The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.